Clinical trials: Neoplasm, Brain
Acoustic Schwannoma, Adult Anaplastic Meningioma
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Acoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma
- Trial name
- NCT01125046
- Testing
- bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with…
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms
- Trial name
- NCT04543188
- Testing
- PF-07284890, Binimetinib, Midazolam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Glioma, High Grade Astrocytoma
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present…
- Conditions
- Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
- Trial name
- NCT01081223
- Testing
- Cancer vaccine plus immune adjuvant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- TVAX Biomedical
Adult Brain Tumors
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent glioblastoma…
- Trial name
- NCT00387894
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Prados
Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
This phase I/Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced).
- Conditions
- Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Non-Small Cell Carcinoma
- Trial name
- NCT04250545
- Testing
- Sapanisertib, Telaglenastat Hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Seriously Ill Patients, Cancer
Goals of Care Conversations Study
The long term goal is to improve quality of care in Veterans with serious illnesses by aligning medical care with Veterans' goals and values.
- Conditions
- Seriously Ill Patients, Cancer, Heart Failure, Interstitial Lung Disease
- Trial name
- LSTDI (NCT05001009)
- Testing
- Clinician Implementation Strategy Stage 1: low intensity clinician training, Clinician Implementation Strategy Stage 2: high intensity clinician training, Low patient engagement
- Where
- 3 sites in United States
- Volunteers
- 2,859 people
- Sponsor
- VA Office of Research and Development
Cognitive/Functional Effects, Metastatic Cancer
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00566852
- Testing
- Memantine, Whole brain radiation therapy
- Where
- 235 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Radiation Therapy Oncology Group
Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first…
- Trial name
- NCT02354508
- Testing
- Pasireotide LAR
- Where
- 50 sites in Argentina, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme
Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma
This is a phase II study of the combination of Avastin and metronomic temozolomide in recurrent malignant glioma patients. The primary objective will be to determine the efficacy of Avastin (bevacizumab) and metronomic…
- Trial name
- NCT00501891
- Testing
- Bevacizumab, Metronomic Temozolomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Small Cell Lung Carcinoma
Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain
This phase I/II trial studies the effects and safety of giving lithium carbonate (lithium) to patients with small cell lung cancer (SCLC) undergoing radiation therapy to the brain (PCI; prophylactic cranial irradiation).
- Trial name
- NCT01553916
- Testing
- Lithium Carbonate, Prophylactic cranial irradiation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Washington University School of Medicine
Amyloidosis
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
The drugs dexamethasone and bortezomib are both FDA-approved for the treatment of multiple myeloma, a disease very similar to amyloidosis. However, they are currently investigational for the treatment of amyloidosis.
- Trial name
- NCT01083316
- Testing
- Bortezomib, Dexamethasone, Melphalan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Boston Medical Center
Ewing Sarcoma, Neuroblastoma
Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
The investigators hypothesize that this Phase 2 cellular and adoptive immunotherapy study using human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (HCT) followed by an early, post-transplant infusion…
- Conditions
- Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma
- Trial name
- STIR (NCT02100891)
- Testing
- Allogeneic HCT, Donor NK Cell Infusion
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Monica Thakar
Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03087591
- Testing
- Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Brain Metastases
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
The purpose of this research study is to determine the safety of combining lapatinib plus radiation in patients with breast cancer that has spread to the brain.
- Trial name
- NCT00470847
- Testing
- Lapatinib, Whole Brain Radiation, Herceptin
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Nancy Lin, MD
Brain Cancer, Brain Neoplasm, Primary
IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Potential subjects with progressive Grade II primary brain tumor that have IDH1 positive testing from the primary tumor (initial diagnosis) will be offered this treatment study in order to test the safety of the PEPIDH1M vaccine…
- Conditions
- Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor
- Trial name
- RESIST (NCT02193347)
- Testing
- PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid (Td), Temozolomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Katy Peters, MD, PhD
Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention, Heart Disease
Social Work Intervention Focused on Transitions
In response to Program Announcement (PA)-09-164, "NIH Exploratory/Developmental Research Grant Program (R21) a randomized pilot study testing the efficacy of SWIFT: Social Work Intervention Focused on Transitions among at-risk…
- Conditions
- Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention, Heart Disease, Diabetes, Hypertension
- Trial name
- SWIFT (NCT02232126)
- Testing
- SWIFT home intervention
- Where
- 2 sites in United States
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Central Nervous System Lymphoma, Malignant Glioma
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in patients with high-grade brain tumors or cancer…
- Conditions
- Central Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT00103038
- Testing
- 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- OHSU Knight Cancer Institute
Glioma, Anaplastic Astrocytoma
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease in great need of novel therapeutic approaches.
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT03072134
- Testing
- Neural stem cells loaded with an oncolytic adenovirus
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Glioblastoma Multiforme
Amgen 386 for Recurrent Glioblastoma
Primary Objectives Cohort A -- monotherapy: To determine the efficacy of AMG 386 in participants with recurrent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6) Cohort B - combination therapy: Phase I To…
- Trial name
- NCT01290263
- Testing
- Amgen 386, Bevacizumab
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dana-Farber Cancer Institute
Kidney Cancer, Melanoma (Skin)
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00550654
- Testing
- questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institutes of Health Clinical Center (CC)